- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:55 | EC approves Biocon's Stelara biosimilar Yesintek for inflammatory diseases | ||
| 13:55 | BMS shares overall survival results for Opdivo in phase 3 lung cancer trial | ||
| 13:55 | Why patients ignore your trials - how to make clinical trials stand out in the real world among the world's biggest brands | ||
| Do | Biogen gains rights to Stoke's Dravet syndrome candidate in deal worth $550m | ||
| Do | FDA grants RMAT designation to AskBio's Parkinson's gene therapy candidate | ||
| Do | EC approves CSL/Arcturus' self-amplifying mRNA COVID-19 vaccine Kostaive | ||
| Do | Inclusivity, collaboration and targeted care | ||
| Mi | Merck's Welireg granted EC approval for von Hippel-Lindau disease and kidney cancer | ||
| Mi | Sanofi and Regeneron's Dupixent granted FDA priority review for bullous pemphigoid | ||
| Mi | AstraZeneca shares promising phase 3 results for Imfinzi in bladder cancer | ||
| Di | EC approves Galderma's Nemluvio to treat atopic dermatitis and prurigo nodularis | ||
| Di | Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis | ||
| Di | FDA approves Bavarian Nordic's chikungunya vaccine for individuals aged from 12 years | ||
| Mo | GSK's five-in-one meningococcal vaccine Penmenvy granted FDA approval | ||
| Mo | Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer | ||
| Mo | Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A | ||
| 14.02. | AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn | ||
| 14.02. | Roche's Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy | ||
| 14.02. | EC approves CSL's Andembry to prevent hereditary angioedema attacks | ||
| 14.02. | Are we masters of our own health? | ||
| 13.02. | Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma | ||
| 13.02. | FDA approves SpringWorks Therapeutics' Gomekli to treat neurofibromatosis type 1 | ||
| 13.02. | Eli Lilly and OliX partner to advance early-stage metabolic disease candidate | ||
| 12.02. | Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition | ||
| 12.02. | Boehringer's nerandomilast shows promise in phase 3 pulmonary fibrosis study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
